Immunogenicity

N-Linked Glycosylation Limits Immune Response To Hepatitis C

Published in Hepatitis Weekly, December 17th, 2001

by Sonia Nichols, senior medical writer - For years, scientists have been driven to develop a vaccine for hepatitis C virus (HCV) but have failed. New information about viral N-linked glycosylation may soon change that.

"We investigated the role played by N-glycans in the immunogenicity of HCV E1 envelope glycoprotein, a naturally poor immunogen," research collaborators in Europe said in the December 2001 issue of Journal of Virology.

Generating plasmid-based constructs containing E1 protein mutants for which the N-linked glycosylation site had been changed, INSERM investigator A. Fournillier, in conjunction with others at Bio-Merieux,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-12-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry